Creganna-Tactx Medical designs, develops, manufactures, and delivers minimally invasive delivery and access devices. Its products are in a range of MI catheter market segments, including PTCA, PTA, EP, specialty and niche catheters–Atherectomy, CTO, vulnerable plaque, thrombectomy, and GI catheters. The company’s designs and development projects include PTCA and PTA balloon catheters, stent delivery systems, CTO catheters, vulnerable plaque detection catheters, embolic filter device delivery systems, steerable EP catheters and sheaths, Kyphoplasty delivery devices, endoscopic biopsy devices, IVUS and imaging delivery systems, laparoscopic devices, and valve repair/replacement delivery system...
Parkmore West Industrial Estate
Founded in 1980
Creganna-Tactx Medical Opens its First Representative Office in China
Nov 13 13
Creganna-Tactx Medical announced the opening of its first representative office in China. The new office is being established to enable the company build upon its existing presence in the market by forging deeper partnerships with its foreign and domestic customer base in China. The Chinese medical device market continues to grow at 20% per annum and this latest addition to the company's global network reflects the continued commercial opportunity within the region. Located in Shanghai, the office is locally staffed with industry experienced professionals who are expert in all facets of the domestic healthcare market. Along with providing enhanced commercial, technical and customer-service support to the company's customers in China, the team will also assist customers to identify and develop leading products customized to local market requirements.
Creganna-Tactx Medical Announces Management Changes
Jul 31 13
Creganna-Tactx Medical has announced that Robert B. Hance will join the company as Chief Executive Officer in September 2013, taking over the role from Helen Ryan who has held the position for the last eight years. Robert "Chip" Hance has extensive experience in the medical device sector with more than 23 years at Abbott Laboratories, most recently as President of Abbott Vascular. Over a four year period at Abbott Vascular, Hance led a 9,000 person organisation through a period of significant sales growth from $1.7 billion in 2007 to $3.3 billion in 2011, to command global market leadership in the drug eluting stent market. Helen Ryan will take up a new board role as non-executive director.